The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis-Reference-Cited by-同舟云学术

The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis

Published:2021-07 Issue: Volume:120 Page:154779
ISSN:0026-0495
Container-title:Metabolism
language:en
Short-container-title:Metabolism

Author:

Liu Shanshan,Wang Jialu,Wu Shujing,Niu Jingya,Zheng Ruizhi,Bie Lizhan,Xin Zhuojun,Wang Shuangyuan,Lin Hong,Zhao Zhiyun,Wang Tiange,Xu Min,Lu Jieli,Chen Yuhong,Xu Yiping,Wang Weiqing,Ning Guang,Bi Yufang,Li Mian,Xu Yu

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Reference32 articles.

1. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases;Chalasani;Hepatology.,2018

2. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes;Younossi;Hepatology.,2016

3. New trends on obesity and NAFLD in Asia;Fan;J Hepatol,2017

4. Epidemiology and natural history of non-alcoholic fatty liver disease;Fazel;Metabolism.,2016

5. Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999–2014.e1. doi: https://doi.org/10.1053/j.gastro.2019.11.312.

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Arterial stiffness progression in metabolic dysfunction–associated fatty liver disease subtypes: A prospective cohort study;Nutrition, Metabolism and Cardiovascular Diseases;2024-08

2. Association of subclinical carotid artery atherosclerosis assessed by carotid ultrasound with nonalcoholic fatty liver disease fibrosis score in young and middle-aged men;The International Journal of Cardiovascular Imaging;2024-07-16

3. Metabolic dysfunction–associated fatty liver disease is associated with the presence of coronary atherosclerotic plaques and plaque burden;Hellenic Journal of Cardiology;2024-06

4. Reversing Metabolic Dysfunction-Associated Steatotic Liver Disease Promotes Healthy Pediatric Cardiovascular Structures: The PROC Study;American Journal of Gastroenterology;2024-05-07

5. Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges;Metabolism;2024-05